03/13/2026
Your Angelman Strong fundraising efforts are making a real and meaningful impact. Because of this incredible community, important advancements in Angelman syndrome research are happening right nowβbringing us closer to better treatments and, one day, a cure.
Every dollar raised, every mile walked, and every story shared helps fuel the scientists, clinicians, and families who are working tirelessly to change the future for individuals living with Angelman syndrome.
From groundbreaking research studies to expanding clinical trials and increasing awareness around the world, your dedication is helping turn hope into progress.
Thank you for standing strong with us and continuing to move this mission forward. Together, we are making a difference. π
ASF-Funded Research Published!
New findings show that increasing overall UBE3A levels may improve many Angelman-related learning and behavioral challenges. This discovery is an encouraging insight for future gene therapies.
The study also found that seizures appear to be linked to one specific version of the UBE3A protein, helping explain why epilepsy in Angelman syndrome can be especially difficult to treat.
βThe UBE3A gene makes a protein that comes in two different versions β one short form of UBE3A and one longer form. In our study, we explored how each version of UBE3A contributes to certain Angelman syndrome symptoms using a mouse model. We found that most symptoms could be improved with either version of the UBE3A protein. However, seizures associated with Angelman syndrome depended on only one specific version (the shorter form of UBE3A). This information is expected to guide future therapeutic development strategies.β
β Joe Krzeski, first author
UNC Chapel Hill, North Carolina
βOur study highlights the importance of restoring the appropriate versions of the UBE3A protein to address the full spectrum of Angelman syndrome symptoms. This has important implications for gene-therapy approaches aimed at reinstating one or both versions of the UBE3A protein.β
β Ype Elgersma, principal investigator
Erasmus University MC, Rotterdam
This ASF-funded work helps move the field toward smarter, more targeted therapies for the Angelman community.
Discoveries like this happen because of fundraising and participating in events like Angelman Strong. Every donation fuels ASF Funded Research. Thank you for making this happen!
See the published work here: https://www.nature.com/articles/s41380-026-03468-9